MRNS Marinus Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MRNS

Price (delayed)

$1.44

Market cap

$78.69M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.63

Enterprise value

$67.06M

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts ...

Highlights
MRNS's revenue is up by 22% year-on-year
The gross profit has grown by 16% YoY
The equity has dropped by 86% year-on-year and by 69% since the previous quarter
The company's quick ratio has shrunk by 62% YoY and by 36% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.marinuspharma.com
Peers: EGRX SUPN PVCT MDWD

Key stats

What are the main financial stats of MRNS
Market
Shares outstanding
54.64M
Market cap
$78.69M
Enterprise value
$67.06M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.69
Price to sales (P/S)
2.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.16
Earnings
Revenue
$30.99M
EBIT
-$126.05M
EBITDA
-$125.31M
Free cash flow
-$118.11M
Per share
EPS
-$2.63
Free cash flow per share
-$2.2
Book value per share
$0.31
Revenue per share
$0.58
TBVPS
$3.18
Balance sheet
Total assets
$170.91M
Total liabilities
$154.14M
Debt
$108.95M
Equity
$16.77M
Working capital
$124.62M
Liquidity
Debt to equity
6.5
Current ratio
4.07
Quick ratio
3.79
Net debt/EBITDA
0.09
Margins
EBITDA margin
-404.4%
Gross margin
93.8%
Net margin
-456.3%
Operating margin
-424.3%
Efficiency
Return on assets
-70.7%
Return on equity
-264.6%
Return on invested capital
-88.3%
Return on capital employed
-96.7%
Return on sales
-406.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MRNS stock price

How has the Marinus Pharmaceuticals stock price performed over time
Intraday
0%
1 week
0%
1 month
-83.65%
1 year
-82.8%
YTD
-86.75%
QTD
-84.07%

Financial performance

How have Marinus Pharmaceuticals's revenue and profit performed over time
Revenue
$30.99M
Gross profit
$29.06M
Operating income
-$131.49M
Net income
-$141.41M
Gross margin
93.8%
Net margin
-456.3%
MRNS's revenue is up by 22% year-on-year
The company's operating income fell by 17% YoY and by 5% QoQ
The gross profit has grown by 16% YoY
The net income has declined by 6% since the previous quarter

Growth

What is Marinus Pharmaceuticals's growth rate over time

Valuation

What is Marinus Pharmaceuticals stock price valuation
P/E
N/A
P/B
4.69
P/S
2.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.16
The EPS has grown by 5% from the previous quarter
The equity has dropped by 86% year-on-year and by 69% since the previous quarter
The price to book (P/B) is 67% lower than the last 4 quarters average of 14.1 and 42% lower than the 5-year quarterly average of 8.1
The price to sales (P/S) is 86% lower than the last 4 quarters average of 17.8
MRNS's revenue is up by 22% year-on-year

Efficiency

How efficient is Marinus Pharmaceuticals business performance
The ROE has plunged by 55% from the previous quarter
The company's return on assets fell by 17% QoQ
The ROS has contracted by 7% from the previous quarter
The ROIC has declined by 2.9% since the previous quarter

Dividends

What is MRNS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MRNS.

Financial health

How did Marinus Pharmaceuticals financials performed over time
The total assets is 11% more than the total liabilities
The company's quick ratio has shrunk by 62% YoY and by 36% QoQ
Marinus Pharmaceuticals's current ratio has plunged by 60% YoY and by 36% from the previous quarter
The equity has dropped by 86% year-on-year and by 69% since the previous quarter
MRNS's debt is up by 7% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.